Trial Details

TERMINATED
Basic Information
Clinical ID c1699
Identifier NCT04655599
Trial Title Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Trial URL Visit Original Page
Study Information
Study Results

NO
Conditions Irritable Bowel Syndrome
Interventions DRUG: Olorinab|DRUG: Placebo
Participant Information
Sponsor Arena Pharmaceuticals
City Rochester
Country/Region United States
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type INTERVENTIONAL
Phase PHASE1
Time Information
Start Date 2021-01-29
Primary Completion Date 2021-04-13
Completion Date 2021-04-13